GPT-Rosalind (OpenAI) vs Perplexity Comet

Which one should you pick? Here's the full breakdown.

GPT-Rosalind (OpenAI)

C
6.8/10

OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)

Our Pick

Perplexity Comet

A
8.4/10

Perplexity's agentic AI browser -- FREE on all platforms as of 2026-03-18 (previously $200/mo Max-only). iOS, Android, Windows, Mac. Browses the web, executes multi-step tasks, and summarizes pages in-line. Comet Plus ($5/mo) adds premium publisher content

CategoryGPT-Rosalind (OpenAI)Perplexity Comet
Ease of Use3.08.0
Output Quality9.08.0
Value7.09.5
Features8.08.0
Overall6.88.4

Pricing Comparison

FeatureGPT-Rosalind (OpenAI)Perplexity Comet
Free TierNoYes
Starting PriceInvite only$0

Which Should You Pick?

Pick GPT-Rosalind (OpenAI) if...

  • Higher output quality (9 vs 8)

Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.

Visit GPT-Rosalind (OpenAI)

Pick Perplexity Comet if...

  • Easier to use (8 vs 3)
  • Better value for money (9.5/10)
  • Has a free tier

Users who already use Perplexity for search and want an agent browser that can complete multi-step tasks (booking, research, shopping, document summarization) across tabs. Also a strong introduction to the AI-browser category for anyone curious but unwilling to pay $200/mo for a preview -- the 2026-03-18 free rollout makes evaluation risk-free.

Visit Perplexity Comet

Our Verdict

Perplexity Comet is the clear winner here with 8.4/10 vs 6.8/10. GPT-Rosalind (OpenAI) isn't bad, but Perplexity Comet outperforms it across the board. Pick GPT-Rosalind (OpenAI) only if researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access.